|
UHRF1BP1L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.45139999971644E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.60149999992332E-07 |
| Normal-vs-Stage2 |
3.243700E-03 |
| Normal-vs-Stage3 |
2.18649999994547E-07 |
| Normal-vs-Stage4 |
7.03160000004033E-07 |
| Stage1-vs-Stage2 |
4.410400E-01 |
| Stage1-vs-Stage3 |
3.531000E-01 |
| Stage1-vs-Stage4 |
2.546400E-01 |
| Stage2-vs-Stage3 |
1.635200E-01 |
| Stage2-vs-Stage4 |
1.202390E-01 |
| Stage3-vs-Stage4 |
6.597600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.25519999949475E-07 |
| Normal-vs-AfricanAmerican |
1.070090E-02 |
| Normal-vs-Asian |
2.49239999972062E-07 |
| Caucasian-vs-AfricanAmerican |
4.240200E-01 |
| Caucasian-vs-Asian |
2.275200E-01 |
| AfricanAmerican-vs-Asian |
1.166580E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.47290000044265E-07 |
| Normal-vs-Female |
1.60240000002254E-06 |
| Male-vs-Female |
4.545800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.42990000000254E-05 |
| Normal-vs-Age(41-60Yrs) |
1.34159999998218E-07 |
| Normal-vs-Age(61-80Yrs) |
1.4241000000359E-06 |
| Normal-vs-Age(81-100Yrs) |
3.876000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.260200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.814200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.500200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.715800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.681200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.842600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.535900E-02 |
| Classical-VS-Follicular |
6.303600E-01 |
| Classical-VS-Other |
1.766190E-01 |
| Classical-VS-Normal |
3.06869999999737E-06 |
| Tall-VS-Follicular |
3.794600E-01 |
| Tall-VS-Other |
4.158000E-01 |
| Tall-VS-Normal |
3.40639999996117E-06 |
| Follicular-VS-Other |
3.932600E-01 |
| Follicular-VS-Normal |
1.173380E-04 |
| Other-VS-Normal |
1.258090E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.08299999967976E-07 |
| Normal-vs-N1 |
1.59309999969715E-07 |
| N0-vs-N1 |
2.012600E-01 |
|
|
